

Monoclonal Antibodies: Dupixent for Asthma

Men	nber Information				
1.	Last Name:	2. First Name:			
3.	Trillium ID #:	4. Date of Birth:		5. Gender: _	
Pres	criber Information				
1.	Prescriber Name: 2. NPI #:				
3.					
4.	Mailing Address:		City:	State:	Zip:
5.	Phone #:	Ext	Fax #:		
Drug	Information				
1.	Drug Name: Dupixent 2	2. Strength:	3. Quantity per 30) Days:	
4.	Length of Therapy (in Days): 🗆 up to 30 Days 🗆 60 Days 🗆 90 Days 🗆 120 Days 🗆 180 Days 🗆 365 Days 🗅 Other				
Clini	cal Information				
1.	Is the member age 6 years of	i age or older? 🗆 Ves 🗆 Nr	`		
2.	• •	•		oct or greater a	at screening (within the
2.					
_	past six weeks prior to the request for Dupixent)? Yes No Please list eosinophil count:				
3.	Does the member have oral corticosteroid dependent asthma with at least 1 month of daily oral corticosteroid use				
	within the last 3 months? Yes No				
4.	Does the member have inadequate control of asthma symptoms after a minimum of 3 months of compliant use of				
	ONE of the following within the past 6 months: Inhaled corticosteroids and long acting beta2 agonist? Yes No				
	Please list medication tried:				
5.	Will Dupixent be used for the relief of acute bronchospasm or status asthmaticus? \Box Yes \Box No				
6.	Will the member receive dual therapy with another monoclonal antibody for the treatment of asthma? \Box Yes \Box No				
Fo	r continuation of therapy, ple	ase answer questions 1-	7		
7. While on Dupixent, has the member had continued clinical benefit from baseline supported by medical records?					
	□ Yes □ No				
** Please provide medical records documenting the member's current asthma status and response to Dupixent					
treatment**					
ue	attrent				

Signature of Prescriber:

Date:

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.